UNIT-V

BP-604T

BIOPHARMACEUTICS & PHARMACOKINETICS

NONLINEAR PHARMACOKINETICS



» The rate process of drug's ADME are depend upon carrier or enzymes that are substrate specific, have definite capacities and are susceptible to saturation at a high drug concentration.

» In such cases, an essentially first-order kinetics transform into a mixture of first-order and zero-order rate processes and the pharmacokinetic parameters are changed with the size of the administered dose.

» Pharmacokinetics of such drugs are said to be dosedependent. Terms synonymous with it are mixed-order, nonlinear and capacity-limited kinetics.

DETECTION OF NON-LINEARITY IN PHARMACOKINETICS

- There are several tests to detect non –linearity in pharmacokinetics but the simplest ones are:
- 1) First test:- Determination of steady state plasma concentration at different doses.
- 2) Second test:- Determination of some important pharmacokinetic parameters such as fraction bioavailability, elimination half life or total systemic clearance at different doses of drug. Any change in these parameters is indicative to non-linearity which are usually constant.



CAUSES OF NON-LINEARITY



Drug absorption

- Three causes:- I) Solubility / dissolution of drug is rate-limited; Griseofulvin - at high concentration in intestine.
 - II) Carrier mediated transport system; Ascorbic acid saturation of transport system.
 - III) Presystemic gut wall / hepatic metabolism attains saturation; Propranolol.
- These parameters affected F, K_a, C_{max} and AUC.
- A decrease in these parameters is observed in former two causes and an increase in latter cause.

Drug distribution

At high doses non-linearity due to

 Two causes:- I) Binding sites on plasma proteins get saturated; Phenylbutazone.

II) Tissue binding sites get saturated.

- In both cases there is increase in plasma drug concentration.
- Increase in V_d only in (I)
- Clearance with high ER get increased due to saturation of binding sites.



Drug metabolism



- Non-linearity occurs due to capacity limited metabolism, smal changes in dose administration - large variations in plasma concentration at steady state - large intersubject variability.
- Two imp causes:- I) Capacity limited metabolism enzyme &/ cofactor saturation; Phenytoin, Alcohol.

II) Enzyme induction - decrease in plasma concentration; Carbamazepine.

- · Autoinduction in dose dependent concentration.
- Saturation of enzymes decrease in Cl_{ii} increase in C_s.
- · In case of enzyme induction reverse condition.
- Other reasons includes saturation of binding sites, inhibitory effects of the metabolites on the action of enzymes.

Drug excretion

- Two active processes which are saturable,
 - I) Active tubular secretion Penicillin G
 - II) Active tubular reabsorption Water soluble vitamins & Glucose.
- Saturation of carrier systems decrease in renal clearance in case of I & increase in II. Half life also increases.
- Other reasons like forced diuresis, change in urine pH, nephrotoxicity & saturation of binding sites.
- In case of biliary excretion non linearity due to saturation -Tetracycline & Indomethacin.



Examples of drugs showing nonlinear pharmacokinetics

Causes



GI absorption:-

Saturable transport in gut wall Saturable GI decomposition Intestinal metabolism **Distribution:-**Saturable plasma protein binding Tissue binding **Metabolism:-**Saturable metabolism Enzyme induction Metabolite inhibition **Renal elimination:-**Active secretion Tubular reabsorption Change in urine pH

Riboflavin, Gabapentin Penicillin G, Omeprazole Propranolol, Salicylamide

Phenylbutazone, Lidocaine Imipramine

Phenytion, Salicylic acid Carbamazepine Diazepam

Para- aminohippuric acid Ascorbic acid, Riboflavin Salicylic acid, Dextroamphetamine

MICHAELIS MENTEN ENZYME KINETICS

 It is also called as Capacity-limited metabolism or Mixed order kinetics.

 $E + D \iff ED \longrightarrow E + M$

 Enzymes usually react with the substrate to form enzyme substrate complexes; then the product is formed. The enzyme can go back to react with another substrate to form another molecule of the product. MICHAELIS MENTEN EQUATION The kinetics of capacity limited or saturable processes is best described by Michaelis-Menten equation.

$$-\frac{dC}{dt} = \frac{V_{max} \cdot C}{K_{M} + C} I$$
Where,

$$-dC/dt = rate of decline of drug conc. with time
$$V_{mx} = theoretical maximum rate of the
process
K_{M} = Michaelis constant$$$$

- Three situation can now be considered depending upon the value of $K_{\scriptscriptstyle \rm I\!\!I}$ and C.
- 1) when $K_M = C$:
- under this situation, eq I reduces to,
- $-dC/dt = V_{ma}/2....II$
- The rate of process is equal to half of its maximum rate.
- This process is represented in the plot of dc/dt vs. C. shown in fig.
- If a drug at low conc. undergoes a saturable biotransformation then K_M>>C:




• here, $K_M + C = K_M$ and eq. I reduces to,

-dC/dt =V_{max}C /K_M.....III

- above eq. is identical to the one that describe first order elimination of drug, where $V_m/K_m = K_s$.
- 3) When $K_M \ll C$:
- Under this condition ,K_M+C= C and eq. I will become, -dC/dt =V_{ms}IV

above eq. is identical to the one that describe a zero order process i.e. the rate process occurs at constant rate V_{ma} and is independent of drug conc. E.g. metabolism of ethanol





K_M+C where, V= reaction rate, C= substrate conc. both are used to determine Vmax

& Km.

The velocity of the reaction(V) at various concentration levels of drug(C) are determined either by *in-vitro* experiments or *in-vivo* experiments at constant enzyme levels.


Method 1



By reciprocating equation (1), we get :

$$\frac{1}{V} = \frac{Km \cdot 1}{Vmax \cdot C} + \frac{1}{Vmax} \dots \dots \dots (2)$$

When 1/V is plotted against 1/C, a straight line is obtained with a *slope* of Km/Vmax and an *Intercept* of 1/Vmax. E.g. : A plot of 1/V vs 1/C (shown in the fig. 2) gave an intercept of 0.33μ mol and a slope of 1.65, Now, calculate Vmax and K_M.





Now, Intercept= $1/Vmax = 0.33 \mu$ mol.

 $Vmax = 3 \mu mol/ml min$

Slope = Km/ Vmax So, 1.65 = Km/ Vmax

 $Km = 1.65 \ X \ 3 = 4.95 \mu mol/ml$

X-axis intercept= -1/ Km



CALCULATION OF K_M & V_{MAX} STEADY- STATE CONCENTRATION


 If drug is administered for constant rate IV infusion/ in a multiple dosage regimen, the steady-state conc. is given in terms of dosing rate (DR):

 $DR = C_{sc}Cl_{\tau}$ (1)

 If the steady-state is reached, then the dosing rate = the rate of decline in plasma drug conc. & if the decline occurs due to a single capacity-limited process then eq. I become as:

 From a plot of C_s vs. DR, a typical curve having a shape of hocky-stick is obtained which is shown in fig. 5.

Curve for a drug following nonlinear kinetics By plotting the steady-state concentration against dosing rates






METHODS USED TO DETERMINE THE K_M & V_{MAX} AT STEADY-STATE

- There are three methods which are used to define the Kate
 & V_{max} at steady-state with appreciable accuracy:
- 1) Lineweaver-Burk Plot:- the reciprocal of eq. (2) we get

- If 1/DR is plotted against 1/C_s a straight line is obtained having slope K_M/V_{ms} & y-intercept 1/V_{msx}
- Direct linear plot:-
- Plotting a pair of C_{ss}, i.e.C_{sl},&C_{ss} against corresponding dosing rates DR₁ & DR₂ we get following fig. 6 which gives values K_M &V_{ms}

Direct linear plot for estimation of K_M & V_{max} at steady-state conc. Of a drug, when it is administered at different dosing rates

(C. 1)







Figure 7

Plot of DR vs DR/C_{ss} for determining Km & Vmax

- 3) Graphical method:-
- In this method by rearranging eq. (2) we get

- In graph DR is plotted against DR/Css, a straight line is obtained with slope -K_M & y - intercept Vmax.
- K_{M} & Vmax can be estimated by simultaneous eq. as



• On solving above eq. 5 & 6 we get,

$$K_{M} = \frac{DR_{2} - DR_{1}}{\frac{DR_{1}}{C_{ss \ 1}} - \frac{DR_{2}}{C_{ss \ 2}}} \qquad (7)$$

- By substituting values of DR₁, DR₂, C_{ssl} & C_{ssl} we get value of K_M & from K_M we can found value of V_{max} at steady-state concentration.
- From experimental observations, it shows that $K_{_M}$ is much less variable than $V_{_{\text{mx}}}$

Kindly refer the following

REFERENCE



- Biopharmaceutics and Pharmacokinetics a treatise by Brahmankar DM, Jaiswal SB.
- 2. http://google.co.in
- Biopharmaceutics & pharmacokinetics by Dr. Shobha Rani R. Hiremath.

